Skip to main content
Top
Published in: International Journal of Clinical Oncology 2/2004

01-04-2004 | ORIGINAL ARTICLE

Gemcitabine plus carboplatin; and gemcitabine, docetaxel, and carboplatin combined chemotherapy regimens in patients with metastatic urothelial carcinoma previously treated with a platinum-based regimen: preliminary report

Authors: Senji Hoshi, Chikara Ohyama, Kunio Ono, Atsushi Takeda, Shinichi Yamashita, Takashi Yamato, Akihiro Itoh, Makoto Satoh, Seiichi Saito, Yasuhiro Okada, Fumihiko Sohma, Yoichi Arai

Published in: International Journal of Clinical Oncology | Issue 2/2004

Login to get access
Metadata
Title
Gemcitabine plus carboplatin; and gemcitabine, docetaxel, and carboplatin combined chemotherapy regimens in patients with metastatic urothelial carcinoma previously treated with a platinum-based regimen: preliminary report
Authors
Senji Hoshi
Chikara Ohyama
Kunio Ono
Atsushi Takeda
Shinichi Yamashita
Takashi Yamato
Akihiro Itoh
Makoto Satoh
Seiichi Saito
Yasuhiro Okada
Fumihiko Sohma
Yoichi Arai
Publication date
01-04-2004
Publisher
Springer-Verlag
Published in
International Journal of Clinical Oncology / Issue 2/2004
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-003-0379-8

Other articles of this Issue 2/2004

International Journal of Clinical Oncology 2/2004 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine